Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of 4 mg nicotine mint lozenge for cognitive impairment during nicotine withdrawal
2005-005307-42Phase 4Completed
- Sponsor
- GSK
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in nicotine dependence comparing 4 mg nicotine mint lozenge with Placebo lozenge (2 arms). Primary endpoint: Ability to concentrate (primary). Started Dec 2005; status: completed.
02
Drugs
nicotine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2005-005307-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005307-42.